ID   WM3211
AC   CVCL_6797
SY   WM-3211; WM 3211; WC00045; EST79
DR   cancercelllines; CVCL_6797
DR   Coriell; WC00045
DR   Cosmic; 972286
DR   Cosmic; 1047655
DR   Cosmic; 1155289
DR   Cosmic; 1155541
DR   Cosmic; 1284919
DR   Cosmic; 1303071
DR   Cosmic; 2144978
DR   Cosmic; 2159443
DR   Cosmic; 2163806
DR   DepMap; ACH-002508
DR   ESTDAB; ESTDAB-079
DR   GEO; GSM109036
DR   GEO; GSM156008
DR   GEO; GSM185194
DR   GEO; GSM185195
DR   GEO; GSM188070
DR   GEO; GSM188122
DR   GEO; GSM188195
DR   GEO; GSM188210
DR   GEO; GSM188216
DR   GEO; GSM188233
DR   GEO; GSM188263
DR   GEO; GSM188286
DR   GEO; GSM188295
DR   GEO; GSM188322
DR   IARC_TP53; 26082
DR   Progenetix; CVCL_6797
DR   Rockland; WM3211-01-0001
DR   Wikidata; Q54994241
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=17260012;
RX   PubMed=18632627;
RX   PubMed=22578220;
RX   PubMed=23851445;
RX   PubMed=24576830;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*03:01,24:02; B*07:02; C*07:02; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*04:01:01,15:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gln50Ter (c.148C>T); ClinVar=VCV000220711; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Leu576Pro (c.1727T>C); ClinVar=VCV000375919; Zygosity=Unspecified (PubMed=23851445; PubMed=24576830; Wistar).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Gly (c.724T>G); ClinVar=VCV000376581; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: Coriell; WC00045; probable.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ESTDAB; Wistar
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 12
ST   D19S433: 13,14
ST   D21S11: 29,31.2
ST   D2S1338: 20,24
ST   D3S1358: 15,16
ST   D5S818: 11
ST   D7S820: 10,12
ST   D8S1179: 10,11
ST   FGA: 20
ST   TH01: 6,9.3
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C4022; Acral lentiginous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 31
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=22578220; DOI=10.1111/j.1755-148X.2012.01016.x;
RA   Furney S.J., Turajlic S., Fenwick K., Lambros M.B., Mackay A.,
RA   Ricken G., Mitsopoulos C., Kozarewa I., Hakas J., Zvelebil M.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S., Herlyn M., Murata H.,
RA   Marais R.;
RT   "Genomic characterisation of acral melanoma cell lines.";
RL   Pigment Cell Melanoma Res. 25:488-492(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//